AptuCure Bio
Personalized Therapeutics
Startup Pre-Funding Health Tech & Life Sciences Est. 2015
Total Raised
Undisclosed
Pre-Funding
Last Round
Undisclosed
Team
2
1-10 employees
Confidence
95/100
Patents
1
About
AptuCure Bio is developing AptuBodies, unique revolutionary synthetic aptamer-based nanoparticles mimicking antibody activity, that can be directed virtually against any target. An AptuBody binds non-covalently to the Fab fragment of circulating IgG antibody and thus provides the antibody a new antigen binding domain, targeted to a designed cell surface markers. An AptuBody will complex with any IgG, directing the complex to its target and activating safe natural complement-mediated immune response. The AptuBodies/IgG complex mimics therapeutic antibodies, by binding to cell surface antigens and promote activation of the natural immune system which aimed to kill the target cells, such as the complement system and killer cells. AptuBodies can replace humanized antibodies, for the treatment of cancer, infectious disease, and auto-immune disease.
Classification
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Core Technology
Biologicals
Target Customer
Healthcare & Life SciencesHealthcarePatientsProvidersLife SciencesPharmaceuticals
Business Model
B2B
Tags
immunologypersonalized-medicinecancer-therapypharmaceuticalsinfectious-diseasepharma-companiesbiotechnologyautoimmune-diseases
Details
Product Stage
R&D
Employees
1-10
Exact Count
2
District
Center District
Founded
2015
Registrar
515781102
Locations
Prof. Efrayim Katzir Street 6, Rehovot, Israel
Links
Admin
Last Update
Aug 16, 2023
Verified by
Natalia Golczar
Claimed
Yes
Missing
video or image, funding rounds, news, markets, external profiles
Team (2)
Ofer Nussbaum, Ph.D.
Founder
Founder
Boaz Musafia
Co-Founder & CSO
Founder